About Thomas, McNerney & Partners
Thomas, McNerney & Partners is a venture capital firm founded in 2001. It is primarily based out of Stamford, United States. As of Mar 2017, Thomas, McNerney & Partners has invested in 35 companies. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to HealthTech and High Tech. Most recently it participated in the $***** Series C round of Vertiflex Overall, Thomas, McNerney & Partners portfolio has seen 5 IPOs and 19 acquisitions including key companies like WuXi AppTec, Invitae and Bausch & Lomb. A lot of funds co-invest with Thomas, McNerney & Partners, with names like Domain Associates sharing a substantial percentage of its portfolio.Key Metrics
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series B, Series A & 5 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Thomas, McNerney & Partners' List of Top Investments
Thomas, McNerney & Partners has a portfolio of 35 companies. Their most notable investments are in Virdante Pharmaceuticals and Innopharma.Their portfolio spans across United States, China and Ireland. They have invested in Life Sciences, HealthTech, High Tech and 3 other sectors, across stages such as Series B, Series A and 5 more. Here is the list of top investments by Thomas, McNerney & Partners:1. WuXi AppTec
WuXi AppTec is a provider of a suite of CRO and CDMO services for small molecules, biologics, and medical devices. It offers a suite of services for the research, development, and manufacturing of both small molecules and biologics and also caters to medical device development and has operations all over the globe. They provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. The company built its initial capabilities around discovery chemistry and has further enhanced the integrated services with analytical services, bio-analytical services, process research, process development services, API manufacturing services, DMPK/ADME, discovery biology, pharmacology, formulation, toxicology, genomic services, biologics manufacturing services, antibody, and biological research reagent manufacturing and sales, and most recently clinical research and regulatory services. In 2022, the company recorded annual revenues of $5.84B and a net profit of $1.31B.
Key facts about WuXi AppTec
- Founded Year: 2000
- Location: Shanghai (China)
- Annual Revenue: £10M - £50M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $40M
- Employee Count: 4,155 as on Nov 16, 2025
- Investors: Strait Huifu Industrial Investment Fund Management, HPR Capital and 27 Others
- Latest Funding Round: Post IPO, Apr 02, 2021, $*****
- Highlight: Public
2. Invitae
Provider of home-based genetic tests for individuals. The platform enables users to request a test online with the help of doctors to collect saliva samples to detect genetic diseases. Users can get results online and share them with doctors.
Key facts about Invitae
- Founded Year: 2010
- Location: San Francisco (United States)
- Annual Revenue: $500M - $1B as on Dec 31, 2022
- Stage: Public
- Total Funding till date: $190M
- Employee Count: 675 as on Sep 30, 2026
- Investors: Scheuermann Investment, Perceptive Advisors and 22 Others
- Latest Funding Round: Post IPO, Apr 05, 2021, $*****
- Highlight: Public
Manufacturer of prescription pharmaceutical products and various eye care items. The business produces ophthalmic solutions and medications designed to treat inflammation, eye pain, and viral conditions. Additional offerings include contact lenses and associated lens care accessories. The organization operates a collection initiative focused on recycling contact lenses, lens cases, and various eye care product packaging materials.
Key facts about Bausch & Lomb
- Founded Year: 1853
- Location: Bridgewater (United States)
- Annual Revenue: $1B+ as on Dec 31, 2025
- Stage: Public
- Employee Count: 9,524 as on Sep 30, 2026
- Investors: Welsh, Carson, Anderson & Stowe, Thomas, McNerney & Partners and 2 Others
- Latest Funding Round: Post IPO, Apr 25, 2023, $*****
- Highlight: Public
Developer of therapeutics for the treatment of multiple diseases. The company's drugs include APOKYN (apomorphine hydrochloride injection for Parkinson's disease), CORGARD (nadolol tablets for hypertension, angina pectoris), MYOBLOC (rimabotulinumtoxinB Injection for cervical dystonia), REVONTO (dantrolene sodium injection for anesthetic-induced malignant hyperthermia syndrome) and XADAGO (safinamide tablets for Parkinson's Disease).
Key facts about US World Meds
- Founded Year: 2001
- Location: Louisville (United States)
- Stage: Series B
- Total Funding till date: $149M
- Employee Count: 3 as on Sep 30, 2026
- Investors: Athyrium Capital Management, CRG and 6 Others
- Latest Funding Round: Grant (prize money), Jul 17, 2025, $*****
5. Amarin
Amarin is developing therapies for treating cardiovascular disease. Amarin's lead candidate, AMR101, is currently being studied in two concurrently run pivotal phase III trials. These trials are investigating the efficacy of AMR101 in lowering triglycerides in patients with very high triglycerides and in patients with mixed dyslipidemia who are taking statins.
Key facts about Amarin
- Founded Year: 1991
- Location: Dublin (Ireland)
- Annual Revenue: $100M - $500M as on Dec 31, 2025
- Stage: Public
- Employee Count: 304 as on Sep 30, 2026
- Investors: Avoro Capital, Longitude Capital and 12 Others
- Latest Funding Round: Conventional Debt, Jan 2017, $*****
- Highlight: Public
Thomas, McNerney & Partners' Investments by Stage
Thomas, McNerney & Partners has made 9 investments in Series B stage with an average round size of $25.8M, 8 investments in Series A stage with an average round size of $22.5M and 3 investments in Series C stage with an average round size of $16M.Stage of entry | No. of Investments |
|---|---|
Series B | 9 |
Series A | 8 |
Series C | 3 |
Series D | 2 |
Series E | 2 |
Others | 2 |
Note: We have considered here, only first round of investments
Thomas, McNerney & Partners' Investments by Sector
Thomas, McNerney & Partners has a diverse portfolio, with companies operating in the Life Sciences, Enterprise Applications, HealthTech, High Tech and Internet of Things - Industry Applications. Notably, it has invested in 28 Tech companies, 24 Enterprise (B2B) companies, 12 Software companies and at least 6 companies focusing on Consumer (B2C).Sector | No. of Investments |
|---|---|
Life Sciences | 24 |
Enterprise Applications | 5 |
HealthTech | 3 |
High Tech | 3 |
Internet of Things - Industry Applications | 2 |
Others | 2 |
Note: We have considered here, only first round of investments
Thomas, McNerney & Partners' Investments by Geography
Thomas, McNerney & Partners has made most investments in United States (26).Thomas, McNerney & Partners' recent investments
Thomas, McNerney & Partners has not made any investment in 2026 so far.Here are the most recent investments by Thomas, McNerney & Partners:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Mar 27, 2017 | United States | Series C | 4958 | [+3] | |
Jul 25, 2016 | United States | Series E | 8378 | ||
Nov 11, 2014 | United States | Series B | 7084 | [+1] | |
Oct 13, 2014 | United States | Series F | 6583 | [+10] | |
Aug 15, 2014 | United States | Series C | 6197 |
IPOs and Publicly Listed companies in Thomas, McNerney & Partners' Portfolio
5 of Thomas, McNerney & Partners' portfolio companies have become public. Bausch & Lomb got listed on the New York Stock Exchange (NYSE), in May 2022 at marketcap of $6.3B and WuXi AppTec got listed on the Hong Kong Exchanges (HKG).Here are Thomas, McNerney & Partners' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
May 06, 2022 | - | - | 8080 | |
Dec 14, 2018 | - | - | 3524 | |
Feb 13, 2015 | Dec 10, 2013 | Series E | 8667 | |
Apr 01, 1993 | - | - | 5330 | |
- | Nov 27, 2007 | Series C | 3942 |
Acquired companies in Thomas, McNerney & Partners' Portfolio
19 companies from Thomas, McNerney & Partners' portfolio have been acquired. The most recent acquisition was Zogenix in Jan 2022 by UCB for $*****.Here are Thomas, McNerney & Partners' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jan 19, 2022 | Aug 28, 2006 | Series A | 9143 | |
Nov 24, 2019 | - | - | 3745 | |
Nov 04, 2019 | - | - | 2088 | |
May 09, 2019 | Feb 14, 2011 | Series A | 6665 | |
Feb 12, 2019 | Jun 15, 2011 | Post IPO | 5887 |
Co-investors of Thomas, McNerney & Partners
Over the past 23 years, 117 investors have co-invested in Thomas, McNerney & Partners's portfolio companies. This includes only funds.
- Invested before Thomas, McNerney & Partners: CID Capital, Early Stage Partners and 15 others have invested in rounds before Thomas, McNerney & Partners. There is 1 company where CID Capital has invested before Thomas, McNerney & Partners and 1 company where Early Stage Partners has invested before Thomas, McNerney & Partners.
- Top Co-investors of Thomas, McNerney & Partners: 47 investors entered a company along with Thomas, McNerney & Partners. These include investors like Domain Associates (3 companies).
- Invested after Thomas, McNerney & Partners: A total of 53 investors have invested in Thomas, McNerney & Partners's portfolio after their investments. Top Investors include Oxford Finance (4 companies), Deerfield (3 companies) and Eisai (2 companies).
Recent News related to Thomas, McNerney & Partners
•
Vertiflex ups raise to $45mMassDevice•Mar 27, 2018•Vertiflex, Endeavour Vision, HIG BioHealth Partners, New Enterprise Associates and 3 others
•
H.I.G. Leads $40M Funding for VertiflexCitybizlist•Mar 10, 2017•Vertiflex, Vertiflex, Endeavour Vision, HIG BioHealth Partners and 3 others
•
Invitae raises $120M for its $1,500 gene sequencing test | VentureBeatVentureBeat•Oct 14, 2014•Invitae, The Broe Group, Decheng Capital, Deerfield and 9 others
•
Auspex Raises $35 Million and Appoints Industry Veteran Gerald Proehl to its Board of DirectorsAuspex Pharmaceuticals•Jan 08, 2014•Auspex Pharmaceuticals, Thomas, McNerney & Partners, Panorama Capital, Deerfield and 2 others
•
Auspex Pharmaceuticals Raises $35M |FinSMEsFinSMEs•Jan 08, 2014•Auspex Pharmaceuticals, Thomas, McNerney & Partners, Panorama Capital, Deerfield and 2 others
•
Genesys Capital participates in US$40 Million Series E financing of Invitae - PE HubPE Hub•Dec 11, 2013•Invitae, Genomic Health, Genesys Capital, Casdin Capital and 2 others
•
AxioMed Spine Raises $3.6M in Funding |FinSMEsFinSMEs•Jan 10, 2013•Axiomed, Investor, MB Venture Partners, Reservoir Venture Partners and 2 others
•
Auspex Pharmaceuticals Closes $25 Million Series D FinancingAuspex Pharmaceuticals•Nov 08, 2012•Auspex Pharmaceuticals, Panorama Capital, Thomas, McNerney & Partners
•
Torax Medical Completes $30M Series D Financing |FinSMEsFinSMEs•Sep 20, 2012•Torax Medical, Mayo Clinic, Kaiser Permanente Ventures, Accuitive Medical Ventures and 3 others
•
